Showing 7701-7710 of 8193 results for "".
- Psoriasis Foundation Awards 13 Research Fellowshipshttps://practicaldermatology.com/news/20140721-psoriasis_foundation_awards_13_research_fellowships/2459162/The National Psoriasis Foundation awarded 13 residents and medical students each a one-year, $50,000 fellowship to study psoriasis. The fellowships aim to increase the number of scientists studying and treating psoriatic disease by encouraging promising doctors to dedicate their careers to the study
- Anacor Pharmaceuticals and Sandoz Enter Into an Agreement for the Commercialization of Kerydin in the UShttps://practicaldermatology.com/news/20140721-anacor_pharmaceuticals_and_sandoz_enter_into_an_agreement_for_the_commercialization_of_kerydin_in_the_us/2459163/Anacor Pharmaceuticals, Inc. has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize Anacor's recently approved Kerydin (tavaborole) topical solution, 5% in the US. PharmaDerm, the branded dermatology business of Sandoz
- Promius Pharma Launches New Physician Portal to Track Patient Progress on Zenatanehttps://practicaldermatology.com/news/20140715-promius_pharma_launches_new_physician_portal_to_track_patient_progress_on_zenatane/2459169/A new web-based provider portal from Promius Pharma allows physicians to follow a patient's progress while taking Zenatane™(isotretinoin capsules USP) AB rated to Accutane. Designed to allow any authorized prescriber using the Promius Promise to obtain easy, instant access to secure patient data rel
- MELA Sciences Begins Insurance Reimbursement Process With Application for New CPT Code for the MelaFind Systemhttps://practicaldermatology.com/news/20140715-mela_sciences_begins_insurance_reimbursement_process_with_application_for_new_cpt_code_for_the_melafind_system/2459170/MELA Sciences, Inc. (Nasdaq:MELA), announced today that it has taken the first step in the process of seeking insurance reimbursement for its Multi-Spectral Digital Skin Lesion Analysis (MSDSLA) procedure that is performed by dermatologists utilizing the MelaFind® system as an aid in the detection o
- Trevi Therapeutics Initiates Pivotal Study of Nalbuphine ER in Uremic Pruritushttps://practicaldermatology.com/news/20140714-trevi_therapeutics_initiates_pivotal_study_of_nalbuphine_er_in_uremic_pruritus/2459171/Trevi Therapeutics recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was well tolerated in hemodialysis patients and established proof-of-concept for Nalbuphine ER in treating uremic pruritus. Trevi's President and Chief Executive Officer, Jennife
- Registration Open for Upcoming ADAM Webinarshttps://practicaldermatology.com/news/20140708-registration_open_for_upcoming_adam_webinars/2459177/The Association of Dermatology Administrators and Managers (ADAM) is offering webinars for practice administrators
- Aclaris Therapeutics Announces Positive Results from Phase II study of Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/20140702-aclaris_therapeutics_announces_positive_results_from_phase_ii_study_of_seborrheic_keratosis_treatment/2459181/Aclaris Therapeutics, Inc. announced positive results from a Phase II clinical trial of the its lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing seborrheic keratoses (SK). The double-bl
- Resident Grants Available for Cosmetic Surgery Forumhttps://practicaldermatology.com/news/20140701-resident_grants_available_for_cosmetic_surgery_forum/2459183/The Cosmetic Surgery Forum 2014, jointly sponsored by the Dulaney Foundation, Practical Dermatology® magazine and Cosmetic Surgery Forum, LLC, will take place December 3 through December 6, 2014 at The Palazzo Hotel Resort & Casino i
- Merz to Acquire Ulthera, Inc.https://practicaldermatology.com/news/20140630-merz_to_acquire_ulthera_inc/2459184/Merz and Ulthera have entered a definitive merger agreement pursuant to which Merz will acquire Ulthera, Inc, a global medical device company focused on developing and commercializing technologies for aesthetic and medical applications using its therapeutic ultrasound platform technology. Valued
- FDA Warns on Acne Productshttps://practicaldermatology.com/news/20140627-fda_warns_on_acne_products/2459185/The FDA warns that using certain acne products containing benzoyl peroxide or salicylic acid can cause rare, but serious and in some cases life-threatening allergic reactions or severe irritation. Certain topical solutions cause: burning, dryness, itching, peeling, redness, and slight sw